Compugen Ltd. (NASDAQ: CGEN): Analyst View Points To Future Growth


ARK Investment Management LLC has recently announced that it has increased stake in Compugen Ltd. (NASDAQ:CGEN) by 36.53%. After grabbing 14.1 million shares, the institutional investor is now in possession of 3.77 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 17.78% having worth around $203.16 million. Moreover, Consonance Capital Management LP increased its share by 4.08 million to have a control over 4.08 million shares. And BlackRock Fund Advisors raised its holdings to 1.55 million shares by acquiring 2.1 million shares or 2.65% of the stake.

Compugen Ltd. (CGEN) concluded trading on 08/26/20 at a closing price of $18.72, with 2.31 million shares of worth about $43.3 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -1.21% during that period and on Wednesday the price saw a loss of about -3.75%. Currently the company’s common shares owned by public are about 81.27M shares.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 7 analysts are covering the CGEN stock and their offered price forecasts bring an average price target of $20.71. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $28.00 and could fall to a lowest price of $18.00. Analysts also issued an outlook of 1.50 for the Compugen Ltd. stock for next 12 months. The stock’s current price level is 5.22% above of average price target set by the analysts, while a rise to estimated low would result in loss of -4.0 for the stock. However, touching the estimated high of $28.00 would mean a gain of 33.14% for the stock.

ARK Innovation ETF, Nikko AM Global Umbrella Fund – A, and ARK Genomic Revolution ETF are the top 3 mutual funds which are holding stakes in Compugen Ltd. ARK Innovation ETF is currently holding 10.3 million shares of worth totaling $148.42 million. The company recently came buying 0.11 million shares which brought its stake up to 12.99% of the company’s outstanding shares. Nikko AM Global Umbrella Fund – A bought 6.1 million shares, after which its hold over company’s outstanding shares expand to 7.78%, leaving 6.17 million shares with the mutual fund that have a worth of about $88.89 million. ARK Genomic Revolution ETF, after selling 5.74 million shares, have now control over 7.24% of the stake in the company. It holds 27393.0 shares of worth $82.7 million.

Compugen Ltd. (NASDAQ: CGEN) started trading at $19.53, above $0.08 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $18.72, or with a loss of -3.75%. Stock saw a price change of -1.21% in past 5 days and over the past one month there was a price change of 30.00%. Year-to-date (YTD), CGEN shares are showing a performance of 214.09% which increased to 368.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.64 but also hit the highest price of $19.89 during that period. While comparing its average daily trading volume of 1.43 million shares, we see that about 2.31 million changed hands on the day. The stock is currently trading 9.99% above its 20-day simple moving average (SMA20), while that difference is up 17.12% for SMA50 and it goes to 72.20% higher than SMA200.

ARK Investment Management LLC acquired 14.1 million shares of Compugen Ltd. having value of about $203.16 million. Data submitted at the U.S SEC by ARK Investment Management LLC revealed that the firm now holds 3.77 million shares in the company valued at close to $70613019.36, or have control over 36.53% stake in the company. Compugen Ltd. (NASDAQ: CGEN) currently have 81.27M outstanding shares and institutions hold larger chunk of about 48.40% of that. Holding of mutual funds in the company is about 13.66% while other institutional holders and individual stake holders have control over 36.18% and — of the stake respectively.

The stock has a current market capitalization of $1.52B and its 3Y-monthly beta is at 2.78. It has posted earnings per share of -$0.37 in the same period. It has Quick Ratio of 17.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CGEN, volatility over the week remained 6.24% while standing at 6.78% over the month.

Analysts are in expectations that Compugen Ltd. (CGEN) stock would likely to be making an EPS of -$0.09 in the current quarter, while forecast for next quarter ESPS is -$0.1 and it is -$0.46 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.1 which is -$0.08 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -5.10% while it is estimated to decrease by -24.30% in next year.

Analysts at 7 brokerage firms have issued recommendations for the Compugen Ltd. (CGEN)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 7 Wall Street analysts, 7 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on May 26, 2020 offering a Mkt outperform rating for the stock and assigned a target price of $18 to it. Coverage by Stifel stated Compugen Ltd. (CGEN) stock as a Buy in their note to investors on May 13, 2020, suggesting a price target of $19 for the stock. On May 07, 2020, SVB Leerink Initiated their recommendations, while on April 22, 2020, ROTH Capital Initiated their ratings for the stock with a price target of $28. Stock get a Buy rating from SunTrust on March 24, 2020.


Please enter your comment!
Please enter your name here